Sanorell Pharma Gmbh & Co.

Other

Haemopep Pharma Gmbh

Pharma Bissendorf Peptide Gmbh

Gerhard Becker

Wolf-Georg Forssmann

Franz Herbst

Jeanette M Alt

Susanne Koch

Reiner Heidl

Paul Marcel Larson

Pharmaceutical composition which is stable during storage and contains a

This invention provides a process for checking the removal rate of pyrogenic substances, in particular viruses, from organic material. The material to be purified is passed through an ultrafilter or an ultrafiltration unit whose virus-removal rate has already been determined by passing viruses of the Leviviridae family or other comparable small bacteriophages through the filter or filtration unit, the virus titer is determined before and after the filtration operation and the virus removal rate thus calculated. Before or after determining the virus-removal rate, a given pressure is applied to the filter or filtration unit in a gas pressure-hold test, and the decrease in the pressure over a given period is measured. After filtration of the biological material, the rate of virus removal by the filter is checked by repeating the pressure-hold test.

method of checking the rate of removal of pyrogenic substances, in

Described is a peptide fragment which comprises the amino acid sequence 95-126 of ANF/CDD 1-126 (gamma-hANaP) and is formed in the kidney. The fragment urodilatin (ANF/CDD 95-126) has the following amino acid sequence: ##STR1## wherein R.sup.1 and R.sup.2 each represent further peptide fragments of ANF/CDD 1-126 (gamma-hANaP). In the amino acid sequence R.sup.1 is Thr-Ala-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser and R.sup.2 is Asn-Ser-Phe-Arg-Tyr. Further described are processes for the preparation and/or recovery of the new peptide fragment and a medicament containing urodilatin (ANF/CDD 95-126) as well as medical indications of the medicament.

Cardiodilatin fragment, process for preparing same and use thereof

Described is a peptide fragment which comprises the amino acid sequence 95-126 of ANF/CDD 1-126 (gamma-hANaP) and is formed in the kidney. The fragment urodilatin (ANF/CDD 95-126) has the following amino acid sequence: ##STR1## wherein R.sup.1 and R.sup.2 each represent further peptide fragments of ANF/CDD 1-126 (gamma-hANaP). In the amino acid sequence R.sup.1 is Thr-Alo-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser and R.sup.2 is Asn-Ser-Phe-Arg-Tyr. Further described are processes for the preparation and/or recovery of the new peptide fragment and a medicament containing urodilatin (ANF/CDD 95-126 ) as well as medical indications of the medicament.

Growing community of inventors

Neckargemund, Germany

Gerhard Becker